CA2360311C - Solutions de dialyse et methodes de dialyse ameliorees - Google Patents

Solutions de dialyse et methodes de dialyse ameliorees Download PDF

Info

Publication number
CA2360311C
CA2360311C CA002360311A CA2360311A CA2360311C CA 2360311 C CA2360311 C CA 2360311C CA 002360311 A CA002360311 A CA 002360311A CA 2360311 A CA2360311 A CA 2360311A CA 2360311 C CA2360311 C CA 2360311C
Authority
CA
Canada
Prior art keywords
dialysis
ribose
age
compounds
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002360311A
Other languages
English (en)
Other versions
CA2360311A1 (fr
Inventor
Raja Khalifah
Billy Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center filed Critical University of Kansas Medical Center
Publication of CA2360311A1 publication Critical patent/CA2360311A1/fr
Application granted granted Critical
Publication of CA2360311C publication Critical patent/CA2360311C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositions de dialyse et méthodes de dialyse améliorées qui font intervenir les inhibiteurs AGE (Advanced Glycation End-product) selon l'invention, ainsi que des méthodes permettant de réduire les complications et les troubles associés à la dialyse.
CA002360311A 1999-04-06 2000-04-06 Solutions de dialyse et methodes de dialyse ameliorees Expired - Fee Related CA2360311C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12790699P 1999-04-06 1999-04-06
US60/127,906 1999-04-06
PCT/US2000/009241 WO2000059493A2 (fr) 1999-04-06 2000-04-06 Solutions de dialyse et methodes de dialyse ameliorees

Publications (2)

Publication Number Publication Date
CA2360311A1 CA2360311A1 (fr) 2000-10-12
CA2360311C true CA2360311C (fr) 2003-03-18

Family

ID=22432569

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360311A Expired - Fee Related CA2360311C (fr) 1999-04-06 2000-04-06 Solutions de dialyse et methodes de dialyse ameliorees

Country Status (4)

Country Link
EP (1) EP1165079A2 (fr)
AU (1) AU4078300A (fr)
CA (1) CA2360311C (fr)
WO (1) WO2000059493A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
EP1380290A1 (fr) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht La voie de la structure cross-béta et sa pertinence thérapeutique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011997A1 (fr) * 1990-02-19 1991-08-22 Senju Pharmaceutical Co., Ltd. Inhibiteur de la reaction de maillard
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
JP2001513370A (ja) * 1997-08-07 2001-09-04 グプタ，アジャイ 水溶性ビタミン及び栄養素を含む透析溶液
US6919326B1 (en) * 1998-08-24 2005-07-19 Toshio Miyata Carbonyl-stress improving agent and peritoneal dialysate

Also Published As

Publication number Publication date
WO2000059493A2 (fr) 2000-10-12
AU4078300A (en) 2000-10-23
EP1165079A2 (fr) 2002-01-02
CA2360311A1 (fr) 2000-10-12
WO2000059493A3 (fr) 2001-02-01

Similar Documents

Publication Publication Date Title
US6436969B1 (en) Dialysis solutions and methods
US6228858B1 (en) Advanced glycation end-product intermediaries and post-amadori inhibition
EP0871443B1 (fr) Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori
US7030146B2 (en) Methods for treating diabetic neuropathy
US6750209B1 (en) Advanced glycation end-product intermediaries and post-amadori inhibition
AU762030B2 (en) Methods for inhibiting diabetic complications
US6730686B1 (en) Methods for inhibiting oxidative modification of proteins
US6740668B1 (en) Methods for inhibiting diabetic complications
US6716858B1 (en) Methods for inhibiting diabetic complications
US20030013746A1 (en) Advanced glycation end-product intermediaries and post-amadori inhibition
CA2360311C (fr) Solutions de dialyse et methodes de dialyse ameliorees
WO2000021516A2 (fr) Procedes destines a empecher des complications diabetiques
EP1190713B1 (fr) Zwischenverbindungen von fortgeschrittenen glykosylierung-endprodukten und post-amadorische inhibitor
WO2000022094A2 (fr) Procede permettant d'inhiber la modification oxydative des proteines
MXPA00004785A (en) Advanced glycation end-product intermediaries and post-amadori inhibition
JP2002528419A (ja) 糖尿病性合併症に対する化合物およびその治療的使用
JP2002517738A (ja) 糖尿病患者が糖尿病に伴う病状を経験するリスクの評価方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190408